Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:33 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control
NCT02025465 · CAMC Health System · PHASE4 · terminated · last registry update 2026-09-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low enrollment and PI retired.” | – | Registry record, CAMC Health System |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ADRB1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-28Also stopped (terminated): Algemeen Ziekenhuis Maria Middelares, Plasma-lyte (static group) + Norepinephrine (static group) (NCT06080178)
- 2026-10-28Also stopped (withdrawn): Aarhus University Hospital, Weak steroid (Flurolon, Allergan) + Potent steroid (Maxidex, Alcon) (NCT01682421)
- 2026-10-05Results posted on the registry: Ankara City Hospital Bilkent, Sevoflurane (Volatile Anesthetic) + Propofol 1% (NCT07092046)
- 2026-09-10Phase 3 first posted: Cairo University, Insulin eye drops + standard post-operative topical drops (NCT07812129)
- 2026-08-05Results posted on the registry: Bausch & Lomb Incorporated, a drug against ADRB1 (NCT04840563)
- 2026-06-15Also stopped (terminated): Mayo Clinic, Carvedilol (NCT03879629)
- 2026-05-22Results posted on the registry: Johnson & Johnson Vision Care, Inc., a drug against ADRB1 (NCT06749496)
- 2026-05-13Also stopped (terminated): Washington University School of Medicine, Carvedilol + Empagliflozin (NCT06844669)
- 2026-04-22Results posted on the registry: Beaver-Visitec International, Inc., a drug against ADRB1 (NCT06399211)
- 2026-03-19Also stopped (withdrawn): Centre hospitalier de l'Université de Montréal (CHUM), a drug against ADRB1 (NCT05119270)
- 2025-12-23Phase 3 first posted: Ain Shams University, Balanced anesthesia + Lidocaine spray (NCT07299630)
- 2025-12-11Also stopped (terminated): Hopital Charles Nicolle, Ephedrine (6 mg boluses) + Norepinephrine (10 µg boluses) (NCT07259655)
- 2025-11-20Phase 3 first posted: University of British Columbia, Pharmacological Rate Control (NCT07238452)
- 2025-10-09Results posted on the registry: Abramson Cancer Center at Penn Medicine, Carvedilol (NCT04023110)
- 2025-09-16Also stopped (withdrawn): Alcon Research, a drug against ADRB1 (NCT06592521)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision